Human FOXE1 activation kit by CRISPRa

CAT#: GA101614

FOXE1 CRISPRa kit - CRISPR gene activation of human forkhead box E1



  See Other Versions

CNY 12,255.00


货期*
4周

规格
    • 1 kit

Product images

经常一起买 (3)
Rabbit Polyclonal Anti-FOXE1 Antibody
    • 100 ul

CNY 1,999.00
CNY 3,280.00


FOXE1 (Myc-DDK-tagged)-Human forkhead box E1 (thyroid transcription factor 2) (FOXE1)
    • 10 ug

CNY 5,488.00


Rabbit Polyclonal Anti-FOXE1 Antibody
    • 25 ul

CNY 800.00
CNY 1,280.00

Specifications

Product Data
Format 3 gRNAs (5ug each), 1 scramble ctrl (10ug) and 1 enhancer vector (10ug)
Symbol FOXE1
Locus ID 2304
Kit Components

GA101614G1, FOXE1 gRNA vector 1 in pCas-Guide-GFP-CRISPRa

GA101614G2, FOXE1 gRNA vector 2 in pCas-Guide-GFP-CRISPRa

GA101614G3, FOXE1 gRNA vector 3 in pCas-Guide-GFP-CRISPRa

1 CRISPRa-Enhancer vector, SKU GE100056

1 CRISPRa scramble vector, SKU GE100077

Disclaimer These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPRa SAM technology. The efficiency of the activation can be affected by many factors, including nucleosome occupancy status, chromatin structure and the gene expression level of the target, etc.
Reference Data
RefSeq NM_004473
Synonyms FKHL15; FOXE2; HFKH4; HFKL5; TITF2; TTF-2; TTF2
Summary This intronless gene encodes a protein that belongs to the forkhead family of transcription factors. Members of this family contain a conserved 100-amino acid DNA-binding 'forkhead' domain. The encoded protein functions as a thyroid transcription factor that plays a role in thyroid morphogenesis. Mutations in this gene are associated with the Bamforth-Lazarus syndrome, and with susceptibility to nonmedullary thyroid cancer-4. [provided by RefSeq, Nov 2016]
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Other Versions

Customer Reviews 
Loading...